Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, February 2002

Altmetric Badge

Mentioned by

patent: 8 patents

Citations

dimensions_citation: 170 Dimensions

Readers on

mendeley: 73 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 8 patents that reference this research output.

Cyclophosphamide in combination with immune therapeutics

Grant US-9539267-B2

United States of America

Method of identifying patients not suitable for high-dose cyclophosphamide treatment

Grant US-9279803-B2

United States of America

Method for treating cancer using an antibody that inhibits notch4 signaling

Grant US-9089556-B2

United States of America

Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen

Grant US-9026372-B2

United States of America

Cyclophosphamide in combination with anti-idiotypic vaccines

Grant US-8673321-B2

United States of America

Compositions and methods for treating and diagnosing pancreatic cancer

Grant US-8501472-B2

United States of America

Aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker

Grant US-8435746-B2

United States of America

Compositions and methods for treating and diagnosing pancreatic cancer

Grant US-8148147-B2

United States of America